{{medical}}
{{Drugbox
| verifiedrevid = 462267372
| IUPAC_name = 4-Diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylethanoate
| image = (RS)-Oxybutynin Structural Formula V1.svg
| image2 = Oxybutynin 3d balls.png

<!--Clinical data-->
| tradename = Ditropan 
| Drugs.com = {{drugs.com|monograph|oxybutynin-chloride}}
| MedlinePlus = a682141
| pregnancy_AU = B1
| pregnancy_US = B
| licence_EU = yes
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_US_comment = and OTC
| routes_of_administration = [[口服给药|口服给药]]、{{tsl|en|transdermal||transdermal}} gel、{{tsl|en|transdermal patch||transdermal patch}}

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 91–93%
| metabolism =  
| elimination_half-life = 12.4–13.2 hours

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 5633-20-5
| ATC_prefix = G04
| ATC_suffix = BD04
| ATC_supplemental =  
| PubChem = 4634
| IUPHAR_ligand = 359
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01062
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4473
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = K9P6MC7092
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00465
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 7856
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1231

<!--Chemical data-->
| C=22 | H=31 | N=1 | O=3
| molecular_weight = 357.486 g/mol
| smiles = O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C2CCCCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XIQVNETUBQGFHX-UHFFFAOYSA-N
}}

'''奧昔布寧'''（Oxybutynin），商品名'''Ditropan'''、'''Lyrinel XL'''、'''Lenditro''' <small>([[南非|ZA]])</small>、'''Driptane''' <small>([[俄罗斯|RU]])</small>、'''Uripan''' (Middle East)<ref>{{cite web|title=Uripan Tablets|url=http://www.adwia.com/index.php?option=com_content&view=article&id=212&Itemid=274&lang=en|publisher=Adwia Pharmaceuticals|accessdate=22 November 2015}}</ref>，為一種[[抗膽鹼劑|抗膽鹼劑]]，可以緩解膀胱排尿困難，包含頻尿及[[尿失禁|尿失禁]]等症狀，可以降低膀胱肌肉痙攣<ref>Chapple CR. "Muscarinic receptor antagonists in the treatment of overactive bladder". ''Urology'' (55)5, Supp. 1:33-46, 2000.</ref>。本品也可用於幫助緩解與腎結石相關的症狀。

本品可競爭性[[受体拮抗剂|拮抗]]{{tsl|en|Muscarinic acetylcholine receptor M1||M<sub>1</sub>}}、{{tsl|en|Muscarinic acetylcholine receptor M2||M<sub>2</sub>}}，及{{tsl|en|Muscarinic acetylcholine receptor M3||M<sub>3</sub>}}等[[蕈毒鹼型乙醯膽鹼受體|蕈毒鹼型乙醯膽鹼受體]]。

本品可能也可用於治療[[多汗症|多汗症]]<ref>{{cite journal |vauthors=Tupker RA, Harmsze AM, Deneer VH | title = Oxybutynin therapy for generalized hyperhidrosis. | journal = Arch Dermatol | volume = 142| issue = 8 | pages = 1065–6| year = 2006 | pmid = 16924061 | doi = 10.1001/archderm.142.8.1065 }}</ref><ref>{{cite journal |vauthors=Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC | title = Oxybutynin: dry days for patients with hyperhidrosis. | journal = Neth J Med  | volume = 64 | issue = 9 | pages = 326–8| year = 2006 | pmid = 17057269 }}</ref><ref>{{cite journal |vauthors=Schollhammer M, Misery L | title = Treatment of hyperhidrosis with oxybutynin. | journal = Arch Dermatol.  | volume = 143 | issue = 4 | pages = 544–5| year = 2007 | pmid = 17438194 | doi = 10.1001/archderm.143.4.544 }}</ref>。

==立體化學==
奧昔布寧含有一個立體中心，由兩種對映體組成。這是外消旋體，即1：（R）的1:1混合物 - 和（S）形式:<ref>Kachur JF, et al. ''R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine'', ''[[Journal_of_Pharmacology_and_Experimental_Therapeutics|Journal of Pharmacology and Experimental Therapeutics]]'', 247, S. 867–872, 1988; PMID 2849672.</ref><ref>Noronha-Blob L, Kachur JF. ''Enantiomers of oxybutynin: in vitro pharmacological characterization at M<sub>1</sub>, M<sub>2</sub> and M<sub>3</sub> muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs'', ''[[Journal_of_Pharmacology_and_Experimental_Therapeutics|Journal of Pharmacology and Experimental Therapeutics]]'', 256, S. 562–567, 1991; PMID 1993995.</ref>

{| class="wikitable" style="text-align:center"
|- class="hintergrundfarbe6"
! colspan="2"| 奧昔布寧的對映體
|-
| [[File:(R)-Oxybutynin_Structural_Formula_V1.svg|250 px]]<br /><small> CAS-Nummer: 119618-21-2</small>
| [[File:(S)-Oxybutynin_Structural_Formula_V1.svg|250 px]]<br /><small> CAS-Nummer: 119618-22-3</small>
|}

== 參考文獻 ==
{{Reflist|2}}

== 外部連結 ==
* https://web.archive.org/web/20090207085759/http://health.yahoo.com/urinary-medications/oxybutynin-oral/healthwise--d00328a1.html
* http://www.mayoclinic.com/health/drug-information/DR601047
* http://www.medicinenet.com/oxybutynin_er-oral/article.htm

{{Urologicals}}
{{Hallucinogens}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:醇|Category:醇]]
[[Category:炔烃|Category:炔烃]]
[[Category:胺|Category:胺]]
[[Category:羧酸酯|Category:羧酸酯]]
[[Category:蕈毒碱性受体拮抗剂|Category:蕈毒碱性受体拮抗剂]]